THE TALK: Gastrointestinal Cancers A Review of Data from the ESMO 2021 Virtual Meeting - Episode 4

ESMO 2021 Updates in Gastric Cancer and Colorectal Cancer

, , ,

Sam Klempner, MD; Daniel H. Ahn, DO; Nataliya V. Uboha, MD, PhD; and Manish A. Shah, MD, FASCO, review recent updates in second-line gastric cancer, CAR T-cell therapy in solid tumors, and colorectal cancer presented at ESMO 2021.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: ESMO 2021 Updates in Metastatic Esophageal Squamous Cell Carcinoma
    EP. 2: ESMO 2021 Updates in Gastroesophageal and Gastric Adenocarcinomas
    EP. 3: ESMO 2021 Updates in HER2+ Metastatic Gastric and Gastroesophageal Cancer
    Now Viewing
    EP. 4: ESMO 2021 Updates in Gastric Cancer and Colorectal Cancer

    Data from the following clinical trials are discussed:

    • 1382P - Phase 1b/2 open-label, randomized evaluation of second-line atezolizumab (atezo) + linagliptin (lina) vs ramucirumab (ram) + paclitaxel (pac) in MORPHEUS-gastric cancer (MORPHEUS)
    • 1372O - CLDN 18.2-targeted CAR-T cell therapy in patients with cancers of the digestive system
    • LBA6 - KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation KRYSTAL-1
    x